Wednesday, April 23, 2014

Byron Capital ups Cipher price target

Byron Capital ups Cipher price target

May 6, 2013 by · Leave a Comment 

Tweet Byron Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $6.25 from $5.25, after the company posted record results for the first quarter. The stock closed at $3.80 on Friday. “Our key takeaway is the Absorica launch is outperforming even our optimistic expectations,” writes analyst Doug Loe. On Absorica’s […]

Byron Capital lifts Transition price target

Byron Capital lifts Transition price target

May 1, 2013 by · Leave a Comment 

Tweet Bryon Capital Markets has raised its price target on “speculative buy-rated” Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) to $5.25 from $3.25 after the company reported positive top-line data from its Phase 1/2 trial with 60 Type 2 diabetic patients, testing Eli Lilly’s GLP-1-glucagon dual agonist peptide drug TT-401 as a once-weekly blood glucose-lowering and weight loss […]

OncoGenex’s OGX-427 drug gaining investor attention

OncoGenex’s OGX-427 drug gaining investor attention

March 26, 2013 by · Leave a Comment 

http://www.youtube.com/watch?v=3q82Rl_y8Rc’]

Tweet Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second generation antisense drug, OGX-427. “We have data in bladder and prostate cancer with OGX-427 that, we believe, indicates clinical activity,” co-founder, president and CEO, Scott Cormack, says in […]

Bryon Capital ups Cipher price target to $5.25

Bryon Capital ups Cipher price target to $5.25

March 1, 2013 by · Leave a Comment 

Tweet Bryon Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $5.25 from $4.50 after the drug developer posted record results for 2012. The stock closed at $2.90, up 45 cents, or 18% on Friday. Analyst Doug Loe said his target is still based on 15 times estimated 2015 results, […]

Byron Capital ups Transition Therapeutics to buy

Byron Capital ups Transition Therapeutics to buy

February 12, 2013 by · Leave a Comment 

Tweet Byron Capital has upgraded Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to “buy” from “hold” and raised its price target to $3.25 from $2.25 after the company reported fiscal third quarter results and updated its pipeline activities. The stock was quoted at $2.20 on Tuesday morning. Current activities include two sizable Phase 2 CNS trials testing Transition’s […]

Bryon Capital ups Novadaq to buy

Bryon Capital ups Novadaq to buy

February 7, 2013 by · Leave a Comment 

Tweet Byron Capital Markets has upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “buy” from “hold” and raised its price target to $15 from $12, after the medical imaging company reported strong fourth quarter results this morning. The stock was changing hands at $9.27 Thursday afternoon. “We maintain our positive view on pace of SPY adoption in […]

Byron Capital starts Cipher at buy

Byron Capital starts Cipher at buy

February 4, 2013 by · Leave a Comment 

Tweet Byron Capital Markets has upped Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to a “buy” rating from an “idea of interest” last year with a price target of $4.50, after introducing formal EBITDA forecasts and a valuation for Cipher’s approved product portfolio. The stock closed at $2.70 on Friday. Analyst Doug Loe writes that Cipher’s “risk profile […]

Transition partner begins Phase 2 bipolar trial

Transition partner begins Phase 2 bipolar trial

August 31, 2012 by · Leave a Comment 

Tweet Transition Therapeutics’ (TSX:TTH; NASDAQ:TTHI) licensing partner, Elan Corp., has begun a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes. As the first patient has been dosed in this study, Transition […]

Novadaq revenue beats analysts’ expectations

Novadaq revenue beats analysts’ expectations

August 3, 2012 by · Leave a Comment 

Tweet Second quarter revenue of $5.4-million for Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) beat consensus, prompting several analysts to say they are encouraged that the demand for Novadaq’s SPY imaging remains strong. Spencer Nam of ThinkEquity writes Novadaq has the potential to exceed the Street’s expectations over the next 12-to-24 months, implying that the company could reach […]

Byron Capital ups Novadaq price target

Byron Capital ups Novadaq price target

March 7, 2012 by · Leave a Comment 

Tweet Byron Capital Markets has raised its 12-month price target on “buy-rated” Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to $12 from $11 after the company received an out-patient reimbursement code from the U.S. Centers for Medicare & Medicaid Services (CMS). The CMS decision puts in place a “clear mechanism by which SPY utilization in out-patient surgery – […]

Next Page »

Google+